Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1341)	12/3/1997 12:31:00 AM
From: james	Read Replies (2) \| Respond to of 4676

mz,which one is a genomics co these days? Heard any story about incyte? regards

To: Miljenko Zuanic who wrote (1341)	12/3/1997 11:40:00 AM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 4676

Miljenko, regarding <<For instance, Roche do not have strong in-house cancer program and they are simply bailing out.>> what some say is that they are shifting a lot of that to Genentech, of which they already own ~60% and have an option to buy the rest, but, as you say, not exactly in-house. Current Genentech projects in advanced clinical development are large molecules, but small molecules are coming too. But no kidding about knife in the back. PB